Clinical Trials Directory

Trials / Completed

CompletedNCT02262533

Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Bristol-Myers Squibb · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGApixaban
DRUGAtenolol

Timeline

Start date
2007-06-01
Primary completion
2007-06-01
Completion
2007-06-01
First posted
2014-10-13
Last updated
2015-08-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02262533. Inclusion in this directory is not an endorsement.